Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07215273 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 24 → 28 locations
  2. Study sites: 23 to 24
  3. Primary endpoints: details revised at 2 of 2 entries Show 4 more changesShow less
    • Study sites: 22 to 23
    • Eligibility criteria expanded, about 40 words
    • Secondary endpoints: details revised at 2 of 3 entries
    • Publications: details revised at 44 of 56 entries
  4. Study sites: 21 to 22v14
  5. Study sites: 20 to 21v13
Show 2 earlier versionsHide 2 earlier versions
  1. Study sites: 19 to 20v12
  2. Study sites: 18 to 19v11
  1. Trial sites expanded: 15 → 18 locationsv10
  2. Trial sites expanded: 12 → 15 locationsv9
  3. Study sites: 11 to 12v8
  4. Study sites: 9 to 11v7
  5. Study sites: 8 to 9v6
  6. Study sites: 6 to 8v5
  7. Enrollment reduced: 80 → 60 participantsv4 Show 9 more changesShow less
    • Trial sites expanded: 2 → 6 locations
    • Primary and study completion pushed from Nov 2026 to Dec 2026
    • Start date changed from estimate of Feb 2026 to Feb 13, 2026
    • Interventions: Antifungal Comparator (Drug), EL219 (Drug) to Active Comparator- IV Antifungal (LAmB or voriconazole) (Drug), EL219 (Drug)
    • Secondary endpoints: 6 to 3
    • Study description expanded, about 8 words
    • Publications: 44 to 56
    • Eligibility criteria expanded, about 5 words
    • Study title shortened, about 3 words
  8. Start date: Dec 2025 to Feb 2026
    • Study sites: 1 to 2
    v3
  9. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date: Nov 2025 to Dec 2025
    v2
  10. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine if EL219 is safe and effective compared to liposomal amphotericin B (LAmB) or voricanozole for early treatment of invasive mould infections
Trial Details
NCT Number NCT07215273
Lead Sponsor Elion Therapeutics, Inc.
Conditions
(from sponsor)		 Invasive Mould Infection
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov